Odyssey Therapeutics is a technology company.
Odyssey Therapeutics has raised $700.0M across 4 funding rounds.
Odyssey Therapeutics has raised $700.0M in total across 4 funding rounds.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and protein therapeutics to treat autoimmune and inflammatory diseases by targeting upstream signaling in the innate immune system.[1][2] It addresses unmet needs in conditions like ulcerative colitis, rheumatoid arthritis, and Crohn's disease, with its lead program OD-07656—a RIPK2 inhibitor—set to enter Phase 2a trials in 2025 and 2026, serving patients seeking deeper remission beyond current standards.[1][2][3] Backed by experienced drug hunters and a scalable drug discovery model, Odyssey employs 151 people and focuses on precise pathology targeting in large patient populations.[1][4]
Founded in 2021 in Boston, Massachusetts, Odyssey emerged from a vision to redefine inflammatory disease treatment through novel immune system targeting.[1][2][5] Led by CEO Gary D. Glick, Ph.D., a seasoned biotech leader, the company assembled a team of "drug hunters" with expertise in immunology, medicinal chemistry, and structural biology, including key executives like COO Julie Clauss, CFO Jason Haas, and board chair Jeffrey M. Leiden, M.D., Ph.D.[1][2][4] Early traction came from prioritizing validated targets in high-need areas like IBD and oncology, rapidly advancing programs toward the clinic with backing from top investors like Catalio Capital, marking pivotal momentum in a competitive biotech landscape.[3]
Odyssey stands out in biotech through:
Odyssey rides the wave of precision immunology, capitalizing on advances in structural biology and AI-driven discovery to tackle "intractable" inflammatory conditions amid rising autoimmune disease prevalence.[2][3][5] Timing aligns with post-pandemic demand for safer, more effective therapies beyond biologics like vedolizumab, in a $100B+ market for IBD and arthritis where novel mechanisms promise differentiation.[1][3] It influences the ecosystem by validating novel drugging strategies, attracting syndicate funding, and accelerating clinical shots-on-goal, potentially reshaping standards for large patient populations.[3][4]
Odyssey's near-term catalysts—Phase 2a data readouts starting Q1 2025—could validate its immune-targeting bet, fueling pipeline expansion into oncology and more autoimmune indications.[1][3] Trends like AI integration in drug design and combo therapies will amplify its edge, with potential for partnerships or acquisitions as remission-focused drugs gain traction.[2][5] Its influence may grow by pioneering upstream interventions, evolving from clinical-stage player to transformative force in biotech, ultimately delivering the "extraordinary leaps" in patient outcomes it promises.[4]
Odyssey Therapeutics has raised $700.0M in total across 4 funding rounds.
Odyssey Therapeutics's investors include Dimension Capital, General Catalyst, OrbiMed, SR One, Third Rock Ventures, Atlas Venture, EQT Life Sciences, f7 Ventures, Foresite Capital, Pivotal bioVenture Partners, Soffinova Partners.
Odyssey Therapeutics has raised $700.0M across 4 funding rounds. Most recently, it raised $210.0M Series D in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $210.0M Series D | Dimension Capital, General Catalyst, OrbiMed, SR One, Third Rock Ventures | |
| Dec 1, 2023 | $100.0M Series C | OrbiMed, SR One, Third Rock Ventures | |
| Oct 1, 2022 | $170.0M Series B | Atlas Venture, EQT Life Sciences, f7 Ventures, Foresite Capital, General Catalyst, OrbiMed, Pivotal bioVenture Partners, Soffinova Partners, SR One | |
| Dec 1, 2021 | $220.0M Series A | Atlas Venture, EQT Life Sciences, Foresite Capital, OrbiMed, Pivotal bioVenture Partners, Soffinova Partners, SR One |